TMEFF2 and central nervous system cancer: Compared to the -com group, IDH1+/ATRX+/TP53 + gliomas exhibited lower TMEFF2 promoter methylation (P < 0.001) and higher TMEFF2 mRNA expression (P < 0.001) (Fig. 4f, g).